Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.
The European Medicines Agency (EMA) accepted Pfizer's application to expand its label for blockbuster vaccine Prevenar 13 back in August, and so far, an advisory committee likes what it sees. Read more >>
The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Médecins Sans Frontières. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it. MSF has encouraged the pharma giants to sink the prices on their pneumococcal disease blockers to $5 per child in poor countries, Reuters reports. Pneumococcal shots--Pfizer's Prevenar 13 and GSK's Synflorix--account for about 45% of the cost of fully vaccinating a child against 12 diseases, MSF says. Read more >>
POPULAR COMMENT THREADS
Last week, international charity Médecins Sans Frontières called on Pfizer to drop its price on pneumococcal vaccine Prevenar 13. The pharma giant responded earlier this week, lopping 20 cents off the per-dose cost through vaccine alliance GAVI. But the way MSF sees it, that's not good enough. Read more >>
It's no secret that when serial acquirer and cost-cutting enthusiast Valeant takes over a company, layoffs are on the way. And for Dendreon, the bankrupt Seattle biotech whose assets the Canadian snatched up last month, they've already begun.
In another step forward for cancer vaccine combos, Aduro Biotech announced Thursday that it would start a Phase II trial of its GVAX and CRS-207 for pancreatic cancer with Opdivo, Bristol-Myers Squibb PD-1 drug.
Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.
NewLink's Ebola vaccine tie-up with Merck continues to pay off.
On Tuesday, Bavarian Nordic announced positive survival data from a Phase I combination study of its active prostate cancer immunotherapy candidate Prostvac and Bristol-Myers Squibb's Yervoy (ipilimumab), an immune checkpoint inhibitor.
From Our Sister Sites
Laboratory equipment and services company PerkinElmer announced that it will provide Johnson & Johnson's new San Francisco life science incubator with on-site staff, training and scientific application support.
The FDA has issued a Class 2 recall notice for an electrophysiology cardiac catheter from Biosense Webster, which is a Johnson & Johnson company, due to difficulties with retraction. The recall covers the Lasso NAV Duo Loop eco Catheters. Biosense Webster is the top-performing J&J medical device group as electrophysiology has gained traction of late.